Enoch Cobbina1, Mary R Lee2, Lorenzo Leggio2,3,4, Fatemeh Akhlaghi5. 1. Clinical Pharmacokinetics Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Office 495 A, Avedisian Hall, 7 Greenhouse Road, Kingston, RI, 02881, USA. 2. Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research and National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Bethesda, MD, USA. 3. Medication Development Program, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, MD, USA. 4. Department of Behavioral and Social Sciences, Center for Alcohol and Addiction Studies, Brown University, Providence, RI, USA. 5. Clinical Pharmacokinetics Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Office 495 A, Avedisian Hall, 7 Greenhouse Road, Kingston, RI, 02881, USA. fatemeh@uri.edu.
Abstract
BACKGROUND AND OBJECTIVES: The ghrelin receptor (GHS-R1a) is a potential target for alcohol use disorders. PF-5190457 is the first inverse agonist of GHS-R1a to progress to clinical development with potential to treat alcohol use disorder. We present a population pharmacokinetic model for PF-5190457 in non-heavy (alcohol consumption status = 0) and heavy alcohol drinkers (alcohol consumption status = 1), and identify relevant factors that can influence its pharmacokinetics. METHODS: Plasma concentration-time data from non-heavy (n = 35) and heavy drinkers (n = 12) were pooled for the population pharmacokinetic model development. The influence of various covariates including alcohol consumption status was evaluated. The accuracy, precision, and robustness of the model were also evaluated using bootstrapping and visual predictive checks. RESULTS: A two-compartment model best described the pharmacokinetics of PF-5190457. The apparent volume of distribution of 44.5 L, apparent clearance of 72.0 L/h, apparent peripheral volume of distribution of 271 L, apparent distributional clearance of 28.7 L/h, and first-order absorption rate constant of 0.27/h were accurate and precise. The apparent volume of distribution was 3.8-fold higher (169 L) in heavy drinkers, and correlated with a lower maximum plasma concentration in heavy drinkers compared with non-heavy drinkers at the same dose; and a corresponding reduced incidence of somnolence in heavy drinkers at doses > 50 mg. CONCLUSIONS: This work provides an accurate, precise, and robust two-compartment model that describes the pharmacokinetics of PF-5190457 and suggests a possible link of PF-5190457 pharmacokinetics with somnolence. TRIAL REGISTRATION: ClinicalTrials.gov identifier numbers NCT01247896 and NCT02039349.
BACKGROUND AND OBJECTIVES: The ghrelin receptor (GHS-R1a) is a potential target for alcohol use disorders. PF-5190457 is the first inverse agonist of GHS-R1a to progress to clinical development with potential to treat alcohol use disorder. We present a population pharmacokinetic model for PF-5190457 in non-heavy (alcohol consumption status = 0) and heavy alcohol drinkers (alcohol consumption status = 1), and identify relevant factors that can influence its pharmacokinetics. METHODS: Plasma concentration-time data from non-heavy (n = 35) and heavy drinkers (n = 12) were pooled for the population pharmacokinetic model development. The influence of various covariates including alcohol consumption status was evaluated. The accuracy, precision, and robustness of the model were also evaluated using bootstrapping and visual predictive checks. RESULTS: A two-compartment model best described the pharmacokinetics of PF-5190457. The apparent volume of distribution of 44.5 L, apparent clearance of 72.0 L/h, apparent peripheral volume of distribution of 271 L, apparent distributional clearance of 28.7 L/h, and first-order absorption rate constant of 0.27/h were accurate and precise. The apparent volume of distribution was 3.8-fold higher (169 L) in heavy drinkers, and correlated with a lower maximum plasma concentration in heavy drinkers compared with non-heavy drinkers at the same dose; and a corresponding reduced incidence of somnolence in heavy drinkers at doses > 50 mg. CONCLUSIONS: This work provides an accurate, precise, and robust two-compartment model that describes the pharmacokinetics of PF-5190457 and suggests a possible link of PF-5190457 pharmacokinetics with somnolence. TRIAL REGISTRATION: ClinicalTrials.gov identifier numbers NCT01247896 and NCT02039349.
Authors: William S Denney; Gabriele E Sonnenberg; Santos Carvajal-Gonzalez; Theresa Tuthill; V Margaret Jackson Journal: Br J Clin Pharmacol Date: 2016-10-29 Impact factor: 4.335
Authors: Sravani Adusumalli; Rohitash Jamwal; R Scott Obach; Tim F Ryder; Lorenzo Leggio; Fatemeh Akhlaghi Journal: Drug Metab Dispos Date: 2019-06-10 Impact factor: 3.922
Authors: James C Garbutt; Alexei B Kampov-Polevoy; Robert Gallop; Linda Kalka-Juhl; Barbara A Flannery Journal: Alcohol Clin Exp Res Date: 2010-11 Impact factor: 3.455
Authors: Daniel E Jonas; Halle R Amick; Cynthia Feltner; Georgiy Bobashev; Kathleen Thomas; Roberta Wines; Mimi M Kim; Ellen Shanahan; C Elizabeth Gass; Cassandra J Rowe; James C Garbutt Journal: JAMA Date: 2014-05-14 Impact factor: 56.272
Authors: Gianfabio Giorgioni; Fabio Del Bello; Wilma Quaglia; Luca Botticelli; Carlo Cifani; E Micioni Di Bonaventura; M V Micioni Di Bonaventura; Alessandro Piergentili Journal: J Med Chem Date: 2022-02-14 Impact factor: 7.446